纳武利尤单抗联合伊匹木单抗治疗活动性黑色素瘤脑转移患者的长期结局(CheckMate 204):开放标签、多中心、2期研究最终结果
CheckMate 204研究最终3年随访显示,纳武利尤单抗联合伊匹木单抗在无症状黑色素瘤脑转移患者中颅内临床获益率为57.4%,36个月颅内无进展生存率54.1%、总生存率71.9%;有症状患者获益率16.7%,36个月颅内无进展生存率18.9%、总生存率36.6%。
要点
- 无症状患者颅内临床获益率57.4%,客观缓解率53.5%,完全缓解率33%。
- 无症状患者36个月颅内无进展生存率54.1%,总生存率71.9%。
- 有症状患者颅内临床获益率16.7%,36个月总生存率36.6%。
核心结论
- 无症状黑色素瘤脑转移患者3年持续缓解、总生存和无进展生存支持一线使用纳武利尤单抗联合伊匹木单抗。
- 有症状黑色素瘤脑转移患者治疗仍困难,但部分患者经联合治疗获得长期缓解。
研究设计与样本
- 开放标签、多中心、2期研究(CheckMate 204),纳入165例筛查患者中的119例(72%)接受治疗。
- 无症状患者为队列A(101例),有症状患者为队列B(18例)。
- 给药方案为纳武利尤单抗1 mg/kg联合伊匹木单抗3 mg/kg静脉给药每3周一次共4次,随后纳武利尤单抗3 mg/kg每2周一次最多2年。
主要发现
- 队列A研究者评估颅内临床获益58例(57.4%[95% CI 47.2-67.2]),客观缓解54例(53.5%[95% CI 43.3-63.5]),颅内完全缓解33例(33%)。
- 队列B研究者评估颅内临床获益3例(16.7%[95% CI 3.6-41.4]),客观缓解3例(16.7%[95% CI 3.6-41.4]),颅内完全缓解3例(17%)。
- 队列A 36个月颅内无进展生存率54.1%(95% CI 42.7-64.1),总生存率71.9%(95% CI 61.8-79.8);队列B分别为18.9%(95% CI 4.6-40.5)和36.6%(95% CI 14.0-59.8)。
- 队列A最常见3-4级治疗相关不良事件为丙氨酸氨基转移酶和天冬氨酸氨基转移酶升高(各15例[15%],共101例);队列B无超过1例的3级事件,无4级事件。
- 队列A最常见严重治疗相关不良事件为结肠炎、腹泻、垂体炎和丙氨酸氨基转移酶升高(各5例[5%],共101例);队列B无超过1例的严重事件;队列A有1例治疗相关死亡(心肌炎)。
临床怎么用
- 作者认为,无症状患者3年持续缓解、总生存和无进展生存支持一线使用纳武利尤单抗联合伊匹木单抗。
- 作者认为,有症状黑色素瘤脑转移治疗仍困难,但部分患者经联合治疗获得长期缓解。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combination nivolumab plus ipilimumab was efficacious in patients with asymptomatic melanoma brain metastases (MBM) in CheckMate 204, but showed low efficacy in patients with symptomatic MBM. Here, we provide final 3-year follow-up data from the trial. METHODS: This open-label, multicentre, phase 2 study (CheckMate 204) included adults (aged ≥18 years) with measurable MBM (0·5-3·0 cm in diameter). Asymptomatic patients (cohort A) had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and no neurological symptoms or baseline corticosteroid use; symptomatic patients (cohort B) had an ECOG performance status of 0-2 with stable neurological symptoms and could be receiving low-dose dexamethasone. Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg was given intravenously every 3 weeks for four doses, followed by nivolumab 3 mg/kg every 2 weeks for up to 2 years, until disease progression or unacceptable toxicity. The primary endpoint was intracranial clinical benefit rate (complete responses, partial responses, or stable disease lasting ≥6 months) assessed in all treated patients. Intracranial progression-free survival and overall survival were key secondary endpoints. This study is registered with ClinicalTrials.gov, NCT02320058. FINDINGS: Between Feb 19, 2015, and Nov 1, 2017, 119 (72%) of 165 screened patients were enrolled and treated: 101 patients were asymptomatic (cohort A; median follow-up 34·3 months [IQR 14·7-36·4]) and 18 were symptomatic (cohort B; median follow-up 7·5 months [1·2-35·2]). Investigator-assessed intracranial clinical benefit was observed in 58 (57·4% [95% CI 47·2-67·2]) of 101 patients in cohort A and three (16·7% [3·6-41·4]) of 18 patients in cohort B; investigator-assessed objective response was observed in 54 (53·5% [43·3-63·5]) patients in cohort A and three (16·7% [3·6-41·4]) patients in cohort B. 33 (33%) patients in cohort A and three (17%) patients in cohort B had an investigator-assessed intracranial complete response. For patients in cohort A, 36-month intracranial progression-free survival was 54·1% (95% CI 42·7-64·1) and overall survival was 71·9% (61·8-79·8). For patients in cohort B, 36-month intracranial progression-free survival was 18·9% (95% CI 4·6-40·5) and overall survival was 36·6% (14·0-59·8). The most common grade 3-4 treatment-related adverse events (TRAEs) were increased alanine aminotransferase and aspartate aminotransferase (15 [15%] of 101 patients each) in cohort A; no grade 3 TRAEs occurred in more than one patient each in cohort B, and no grade 4 events occurred. The most common serious TRAEs were colitis, diarrhoea, hypophysitis, and increased alanine aminotransferase (five [5%] of each among the 101 patients in cohort A); no serious TRAE occurred in more than one patient each in cohort B. There was one treatment-related death (myocarditis in cohort A). INTERPRETATION: The durable 3-year response, overall survival, and progression-free survival rates for asymptomatic patients support first-line use of nivolumab plus ipilimumab. Symptomatic disease in patients with MBM remains difficult to treat, but some patients achieve a long-term response with the combination. FUNDING: Bristol Myers Squibb.
引用
- Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021. PMID: 34774225. doi:10.1016/S1470-2045(21)00545-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。